Back to results

CompletedPhase 2

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 Diabetes

NCT01035879

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Impact Clinical Trials

Los Angeles, California, United States

+13 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2009-12
Enrollment: 100 participants
Sponsor: Gilead Sciences
Purpose: treatment

Locations (14)

Impact Clinical TrialsLos Angeles, California, United States
Nevada Alliance Against DiabetesLas Vegas, Nevada, United States
United Medical AssociatesBinghamton, New York, United States
dgd Research, Inc., a Cetero Research Co.San Antonio, Texas, United States
Healthy Life Clinical Diagnostic CenterTbilisi, Georgia
Georgian Diabetes CenterTbilisi, Georgia
Medulla Chemotherapy and Immunotherapy ClinicTbilisi, Georgia
Bharti Research Institute of Diabetes and EndocrinologyKarnāl, Haryana, India
Diabetes Thyroid Hormone Research Institute Pvt LtdIndore, M.p., India
Gandhi Endocrinology & Diabetes CentreRāmdaspeth, Nagpur, India
Gokula Metropolis Research, MS Ramaiah Memorial HospitalBangalore, India
Medisys Clinisearch India Pvt LtdBangalore, India
Hormone Care Research CentreGhaziabad, India
Bangalore Endocrinology & Diabetes Research CentreMalleshwaram, India

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 Diabetes — TrialFind